119-hr1794

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1794 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 1794

 To amend the Federal Food, Drug, and Cosmetic Act to establish an 
 Abraham Accords Office within Food and Drug Administration, and for 
 other purposes.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 March 3, 2025

 Mrs. Harshbarger (for herself, Mr. Vargas, Mr. Weber of Texas, Mr. 
Peters, Mr. Harris of Maryland, and Mr. Levin) introduced the following 
 bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

 A BILL

 To amend the Federal Food, Drug, and Cosmetic Act to establish an 
 Abraham Accords Office within Food and Drug Administration, and for 
 other purposes.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``United States-Abraham Accords 
Cooperation and Security Act of 2025''.

SEC. 2. ESTABLISHMENT OF ABRAHAM ACCORDS OFFICE WITHIN FOOD AND DRUG 
 ADMINISTRATION.

    (a) In General.--Chapter X of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 391 et seq.) is amended by adding at the end the 
following:

``

SEC. 1015. ABRAHAM ACCORDS OFFICE.

 ``

    (a) In General.--The Secretary, acting through the Commissioner 
of Food and Drugs, shall establish within the Food and Drug 
Administration an office, to be known as the Abraham Accords Office, to 
be headed by a director.
 ``

    (b) Office.--Not later than 2 years after the date of enactment 
of this section, the Secretary shall--
 ``

    (1) in consultation with the governments of Abraham 
 Accords countries, as well as appropriate United States 
 Government diplomatic and security personnel--
 ``
        (A) select the location of the Abraham Accords 
 Office in an Abraham Accords country; and
 ``
        (B) establish such office; and
 ``

    (2) assign to such office such personnel of the Food and 
 Drug Administration as the Secretary determines necessary to 
 carry out the functions of such office.
 ``
            (c) Duties.--The Secretary, acting through the Director of the 
Abraham Accords Office, shall--
 ``

    (1) after the Abraham Accords Office is established--
 ``
        (A) as part of the Food and Drug Administration's 
 work to strengthen the international oversight of 
 regulated commodities, provide technical assistance to 
 regulatory partners in Abraham Accords countries on 
 strengthening regulatory oversight and converging 
 regulatory requirements for the oversight of regulated 
 products, including good manufacturing practices and 
 other issues relevant to manufacturing medical products 
 that are regulated by the Food and Drug Administration; 
 and
 ``
        (B) facilitate interactions between the Food and 
 Drug Administration and interested parties in Abraham 
 Accords countries, including by sharing relevant 
 information regarding United States regulatory pathways 
 with such parties, and facilitate feedback on the 
 research, development, and manufacturing of products 
 regulated in accordance with this Act; and
 ``

    (2) carry out other functions and activities as the 
 Secretary determines to be necessary to carry out this section.
 ``
            (d) Abraham Accords Country Defined.--In this section, the term 
`Abraham Accords country' means a country identified by the Department 
of State as having signed the Abraham Accords Declaration.
 ``

    (e) National Security.--Nothing in this section shall be 
construed to require any action inconsistent with a national security 
recommendation provided by the Federal Government.''.

    (b) Report to Congress.--

    (1) In general.--Not later than 3 years after the date of 
 enactment of this Act, the Secretary of Health and Human 
 Services shall submit to the Congress a report on the Abraham 
 Accords Office, including--
        (A) an evaluation of how the Office has advanced 
 progress toward conformance with Food and Drug 
 Administration regulatory requirements by manufacturers 
 in the Abraham Accords countries;
        (B) a numerical count of parties that the Office 
 has helped facilitate interactions or feedback pursuant 
 to 

section 1015
            (c) (1)
        (B) of the Federal Food, Drug, and 
 Cosmetic Act (as added by subsection

    (a) );
            (C) a summary of technical assistance provided to 
 regulatory partners in Abraham Accords countries 
 pursuant to subparagraph
        (A) of such 

section 1015
            (c) (1) ; and
            (D) recommendations for increasing and improving 
 coordination between the Food and Drug Administration 
 and entities in Abraham Accords countries.

    (2) Abraham accords country defined.--In this subsection, 
 the term ``Abraham Accords country'' has the meaning given such 
 term in 

section 1015
            (d) of the Federal Food, Drug, and Cosmetic 
 Act (as added by subsection

    (a) ).
 <all>